CN102475780A - Preparation method 6 for traditional Chinese drug composition for treating primary hypertension - Google Patents
Preparation method 6 for traditional Chinese drug composition for treating primary hypertension Download PDFInfo
- Publication number
- CN102475780A CN102475780A CN201010564324XA CN201010564324A CN102475780A CN 102475780 A CN102475780 A CN 102475780A CN 201010564324X A CN201010564324X A CN 201010564324XA CN 201010564324 A CN201010564324 A CN 201010564324A CN 102475780 A CN102475780 A CN 102475780A
- Authority
- CN
- China
- Prior art keywords
- filter
- extracting solution
- add
- parts
- medicinal residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 208000007530 Essential hypertension Diseases 0.000 title claims abstract description 10
- 239000003390 Chinese drug Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 15
- 239000012530 fluid Substances 0.000 claims abstract description 8
- 244000179560 Prunella vulgaris Species 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 65
- 239000007788 liquid Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 41
- 238000009835 boiling Methods 0.000 claims description 38
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 244000113306 Monascus purpureus Species 0.000 claims description 22
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 22
- 241000237636 Pheretima Species 0.000 claims description 22
- 229940057059 monascus purpureus Drugs 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 18
- 238000002481 ethanol extraction Methods 0.000 claims description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 11
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 11
- 230000008021 deposition Effects 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 102000011759 adducin Human genes 0.000 claims description 7
- 108010076723 adducin Proteins 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 239000000706 filtrate Substances 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract 7
- 239000003640 drug residue Substances 0.000 abstract 6
- 238000010438 heat treatment Methods 0.000 abstract 3
- 238000002791 soaking Methods 0.000 abstract 3
- 238000001556 precipitation Methods 0.000 abstract 2
- 244000025596 Cassia laevigata Species 0.000 abstract 1
- 235000006693 Cassia laevigata Nutrition 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000807 Leonurus cardiaca ssp. cardiaca Nutrition 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 241000108056 Monas Species 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000607122 Uncaria tomentosa Species 0.000 abstract 1
- 235000011472 cat’s claw Nutrition 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 229940124513 senna glycoside Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 30
- 230000036772 blood pressure Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 239000012567 medical material Substances 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 14
- 230000004872 arterial blood pressure Effects 0.000 description 13
- 230000007774 longterm Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 241001529739 Prunella <angiosperm> Species 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000035487 diastolic blood pressure Effects 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000035488 systolic blood pressure Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- -1 electuary Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 3
- 229960002198 irbesartan Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102220099307 rs144750850 Human genes 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000036513 peripheral conductance Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000011706 wistar kyoto rat Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a preparation method for a traditional Chinese drug composition for treating primary hypertension. The composition is prepared by the following preparation method: adding rhubarb (stir-fried with wine) and curcuma to water, soaking, heating until the water is boiled, extracting and filtering, adding water to the resulting drug residue to carry out extraction, filtering, removing the drug residue, and mixing the extracting solutions from the two extraction treatments to obtain an extracting solution 1; adding uncaria tomentosa, obtuseleaf senna seed, and common motherwort fruit to ethanol, soaking, heating until the water is boiled, extracting and filtering, adding ethanol to the resulting drug residue to carry out extraction, filtering, removing the drug residue, and mixing the extracting solutions from the two extraction treatments to obtain an extracting solution 2; adding common selfheal spike, lumbricus, and red monas rice to water, soaking, heating until the water is boiled, extracting and filtering, adding water to the resulting drug residue to carry out decoction, filtering, removing the drug residue, and mixing the extracting solutions from the two extraction treatments, carrying out vacuum concentration to obtain a concentrated solution, cooling to the room temperature, adding an alcohol to carry out alcohol precipitation, standing and filtering, removing the precipitation, concentrating the filtrate to obtain the extracting solution 3; mixing the extracting solution 1, the extracting solution 2 and the extracting solution 3, concentrating the resulting mixture until the fluid extract or the dry powder is obtained.
Description
Technical field
The present invention relates to a kind of field of medicaments, especially relate to a kind of Chinese medicine composition of treating essential hypertension and preparation method thereof.
Background technology
With the metabolism syndrome is the modern civilization disease of representative, closely related with some modern life style, custom etc.Be the high risk factor of type 2 diabetes mellitus and cardiovascular disease, early diagnosis and early intervention metabolism syndrome help the control of type 2 diabetes mellitus and cardiovascular disease.
The definition of metabolism syndrome is core with the central obesity, merges blood pressure, blood glucose, triglyceride rising and/or HDL-C and reduces.Wherein relevant central obesity is adopted waistline as diagnosis index.
Hypertension is that to increase with SAP be the clinical syndrome of main performance, is modal cardiovascular disease, can be divided into essential hypertension and secondary hypertension two big classes; Most hypertension pathogenies are not clear, are called essential hypertension, account for more than 95% of total hypertension; In the patient of less than 5%; Hypertension is a kind of clinical manifestation of some disease, and this is called secondary hypertension in the clear and definite and independently cause of disease.In hypertension prevention and control, exist " three-hypers ", " three is low " phenomenon, three-hypers is that hypertensive sickness rate is high, rate of increase is high, hazardness is high, hypertensive high harm is apoplexy in China, secondly is heart infarction, renal damage; Three low be that hypertensive awareness is low, treatment rate is low, control rate is low.Announced that generaI investigation showed in 04 year, hypertensive awareness is 30.3%, treatment rate 24.7%, control rate 6.1%.Explain that people are to hypertension and hypertensive recognizing dangers wretched insufficiency.
The essential hypertension Chinese patent medicine that antimetabolic syndrome in the market causes is few, and existing medicine belongs to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition of treating essential hypertension.
Another object of the present invention is to provide the method for preparing of said Chinese medicine composition.
Compositions of the present invention, be processed into by the raw material of following weight parts:
Radix et Rhizoma Rhei (stir-fried with wine) 3-12 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5-30 part Semen Cassiae 15-60 part
Ramulus Uncariae Cum Uncis 15-60 part Fructus Leonuri 15-60 part Spica Prunellae 22.5-90 part
Pheretima 15-60 part Monas cuspurpureus Went 3-12 part
Compositions of the present invention, preferably be processed into by the raw material of following weight parts:
Radix et Rhizoma Rhei (stir-fried with wine) 5-7 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 10-20 part Semen Cassiae 20-40 part
Ramulus Uncariae Cum Uncis 20-40 part Fructus Leonuri 20-40 part Spica Prunellae 40-50 part
Pheretima 20-40 part Monas cuspurpureus Went 5-7 part
Compositions of the present invention particularly preferably is by the raw material of following weight parts and is processed into:
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima
In more than forming, weight is calculated with crude drug, and part is a weight portion; If with the gram is unit, more than composition can be made into a pharmaceutical preparation 5-50 preparation unit, and said preparation unit refers to; The final drug preparation of processing, as process solid preparation 5-50 unit, oral liquid 5-50ml etc.
More than form the preparation that can be made into 1-6 taking dose, as as tablet, process 18, each taking dose can be the 3-18 sheet, can take 1-6 time altogether.As as granule, process 6 bags, take the 1-2 bag at every turn, can take 3-6 time altogether.
More than form to be by weight as proportioning; When producing, can increase or reduce according to corresponding proportion; Like large-scale production can be unit with the kilogram, or is unit with the ton, and small-scale production can be unit with the milligram also; Weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and like serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 300%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be by the suitable Chinese medicine replacements with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine composition of the present invention is to process through extraction or other modes through the raw material of Chinese medicine that above-mentioned prescription is formed, and processes pharmaceutically active substance; Subsequently; With this material is raw material, adds the medicine acceptable carrier when needing, and processes according to the routine techniques of galenic pharmacy.Said active substance can obtain through extracting raw material of Chinese medicine respectively; Also can obtain through the co-extracted raw material of Chinese medicine; Also can obtain through other modes; As: through pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, process different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine composition of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical composition of the present invention exists with unit dosage form, and said unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Chinese medicine composition of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.
Chinese medicine composition of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill through mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive; Such as suspending agent; For example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat; Emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, can this chemical compound be suspended or dissolving.The preparation of solution is normally through being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Chinese medicine composition of the present invention; When being prepared into medicament, optionally add suitable medicine acceptable carrier; Said medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Compositions of the present invention is confirmed usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
The method for preparing of the preferred present composition is following:
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 5～10 times of water loggings bubble, 0.5～1h, be heated to boiling after, extract 1～3h, filter, medicinal residues add 5～10 times of water extraction 1～3h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Semen Cassiae, Fructus Leonuri add 5～10 times of 60～95% soak with ethanol 0.5～1h, be heated to boiling after, extract 1～3h; Filter, medicinal residues add 5～10 times of 60～95% ethanol extraction 1～3h, filter; Medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Spica Prunellae, Pheretima, Monas cuspurpureus Went add 5～10 times of water loggings bubble, 0.5～1h, be heated to boiling after, extract 1～3h, filter, medicinal residues add 5～10 times of decoctings and boil 1～3h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 55～65 ℃ are evaporated to density=1.05-1.20, get concentrated solution; After being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 60～90% to supernatant, leaves standstill 12h; Filter, deposition discards, and 55～65 ℃ of concentrating under reduced pressure of filtrating obtain extracting solution 3.
With extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 ℃ are evaporated to fluid extract (density=1.2～1.4) or dry powder.
The active substance that above technology obtains mixes with the medicine acceptable carrier, processes pharmaceutical preparations composition according to the galenic pharmacy routine techniques.
The most preferred method for preparing of the present invention in an embodiment.
Further specify the therapeutic effect of pharmaceutical composition of the present invention through following experiment.
This experiment is the animal drug efficacy study that carries out to the Chinese medicine compound agent, and the animal model of employing is the spontaneous hypertension rat model, and route of administration is an oral administration gavage, and main observation index is mean arterial pressure (MBP).
Mean arterial pressure (MBP)=cardiac output (CO) * total peripheral vascular resistance (PR).
Experimental section mainly comprises dose-effect, the aging research of four kinds of Chinese medicine preparation blood pressure lowering.
One, material and method
(1) experiment material
1, tried thing: comprise that (ZF-7 ZY-1), is provided by sky, Tianjin scholar's power academy Chinese medicine four kinds of Chinese medicine preparation for CT-1, CT-5.Positive drug adopts irbesartan, and (the irbesartan sheet, France produces, the packing of Hangzhou Sanofi-Aventis people's livelihood pharmaceutical Co. Ltd.Lot number of the repackaged products: 0906193. batch number: 1797. dates of manufacture: 2009.02).
2, laboratory animal: adopt spontaneous hypertension rat (SHR), matched group adopts capital of a country Wistar Kyoto rat (WKY).Available from Beijing Vital River Experimental Animals Technology Co., Ltd., the quality certification number: SCXK (capital) 2006-0009.
3, instrument: the non-invasive blood pressure appearance (CODA of U.S. Kent company
TM2).
(2) experimental technique
1. experiment is divided into groups: totally six groups: model group, positive drug group, A, B, C, four administration groups of D.Each group is the SHR rat, and every group of 6-8 only.
2. dosage design: each kind dosage all calculates according to the crude drug amount, obtains following dosage every day.
The design of table 1 dosage
| Group | Sample number into spectrum | Every day is to the crude drug amount | Every day is to the medicated powder amount | Administration every day | The administration volume |
| A | CT-1 | 39.68g/kg | 3.0g/kg | 2 times | 1ml/100g |
| B | CT-5 | 39.68g/kg | 3.6g/kg | 2 times | 1ml/100g |
| C | ZF-7 | 39.68g/kg | 2.0g/kg | 2 times | 1ml/100g |
| D | ZY-1 | 39.68g/kg | 2.8g/kg | 2 times | 1ml/100g |
| Positive group | Irbesartan | 15.5mg/ |
1 time | 1ml/100g |
| Model group | Tap water | 1ml/100g |
3, timeliness experiment: animal is raised a week after arriving laboratory in advance, measures basic blood pressure (basic blood pressure need be measured 1-2 week, guarantees that animal has adapted to instrument, and the blood pressure that measures is a true value).According to the basic blood pressure random packet.Fasting after dividing into groups, gastric infusion, the animal blood pressure of 0h, 12h, 24h after the METHOD FOR CONTINUOUS DETERMINATION administration.After animal detects, begin to carry out the long term administration experiment next day.
4, long-term experiment scheme: animal begins long-term experiment next day after finishing single-dose experiment, every day gastric infusion, successive administration one month.Measure blood pressure weekly once during this time.And grasp the time, guarantee that animal measuring basically at the same time, avoid in the daytime the influence of self fluctuation of blood pressure.Because animal is more, guarantee that consistent (because twice administration every day, the animal that detects afternoon is just given medicine for the first time in the morning to the time point that detects behind every animals administer, draws back delivery time.The animal that detect the morning is given medicine for the first time again after having surveyed.Guarantee that animal does not pass through fierce struggle before tested).Administration stops administration after one month, in convalescent period, the fluctuation situation of blood pressure detects twice weekly after the observation drug withdrawal, continues 2-3 week (looking concrete blood pressure situation).
(3) observation index
1, MAIN OUTCOME MEASURES: blood pressure comprises systolic pressure, diastolic pressure, mean arterial pressure.
2, other: body weight, heart rate, blood biochemical.
Two, experimental result
1, timeliness experiment
According to experimental result, behind single-dose, the blood pressure of each administration group all has certain downward trend.But more all there is not significance to reduce with model group.Heart rate is not found significant change.The result sees table 2,3,4,5
Mean arterial pressure timeliness experiment behind table 2 single-dose.mean±SD
Annotate: and with model group constantly relatively:
* *: p＜0.001
The variation of mean arterial pressure behind Fig. 1 single-dose
The time-effect relationship table that the after-contraction of table 3 single-dose is pressed.mean±SD
Annotate: and with model group constantly relatively:
* *: p＜0.001
The variation that the after-contraction of Fig. 2 single-dose is pressed
The timeliness data of diastolic pressure behind table 4 single-dose.mean±SD
Annotate: and with model group constantly relatively:
* *: p＜0.001
The variation of heart rate behind table 5 single-dose.mean±SD
Annotate: and with model group constantly relatively:
* *: p＜0.001
2, the mean arterial pressure of long term administration experiment changes
According to experimental result, in successive administration one month, the mean arterial pressure that observes each administration group weekly all has certain fluctuation.Two week of administration, the back was to the mean arterial pressure and the model group of each medicine group more all have significance reduction (p＜0.05) all around.The result sees table 3.
Table 6 long term administration is to the influence of each treated animal mean arterial pressure.mean±SD
Annotate: and with model group constantly relatively:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
The variation of a monthly average arterial pressure of Fig. 3 administration.
3, the systolic pressure of long term administration experiment changes
According to experimental result, in successive administration one month, the systolic pressure that observes each administration group weekly all has certain fluctuation.Two week of administration, the back was to the systolic pressure and the model group of each medicine group more all have significance reduction (p＜0.05) all around.The result sees table 4.
Table 7 long term administration is to the influence of each treated animal systolic pressure.mean±SD
Annotate: and with model group constantly relatively:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
The variation that Fig. 4 administration after-contraction in month is pressed.
4, the diastolic pressure of long term administration experiment changes
According to experimental result, in successive administration one month, the diastolic pressure that observes each administration group weekly all has certain fluctuation.Two week of administration, the back was to the diastolic pressure and the model group of each medicine group more all have significance reduction (p＜0.05) all around.The result sees table 5.
Table 8 long term administration is to the influence of each treated animal diastolic pressure.mean±SD
Annotate: and with model group constantly relatively:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
The variation of Fig. 5 administration diastolic pressure after month
5, the changes in heart rate of long term administration experiment
All within normal range, the result sees table 6. to the heart rate of each treated animal
The heart rate influence of table 9 long term administration blood pressure lowering experiment.mean±SD
Annotate: and with model group constantly relatively:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
6, body weight change during the administration.
Each group of spontaneous hypertension rat, month body weight amount of increase of administration is not very big, increasess slowly.
Table 10 long term administration is to the influence of each treated animal body weight.mean±SD
Annotate: and with model group constantly relatively:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
Month the weight of animals of Fig. 6 administration changes
7, administration is after one month, and the blood biochemical of animal changes.
After the administration one month, the blood glucose value of each treated animal does not have significant difference.Also do not have significant difference between each group of ALT, the ALT of CT-1 group has significant reduction (p＜0.05), belongs in the normal physiological scope.The detection of AST finds that the AST of positive drug group compares with model group, obviously increases (p＜0.05).The AST of CT-1, CT-5 group compares with model group, then significantly reduces (p＜0.05).The testing result of TP (total serum protein) shows, removes the ZY-1 group, and the total protein of other each groups is compared with model group, all has and descend significantly (p＜0.001).Sero-abluminous detection finds that each administration treated animal is compared with model group, and albumin is significantly decline (p＜0.01) all.
Lipids detection, administration one month, the triglyceride and the model of CT-1, CT-5 group more all have reduction (p＜0.01) very significantly.After the administration one month, the T-CHOL value and the model group of ZY-1 group significantly increase (p＜0.01).But all the other each administration groups and model group are relatively, and T-CHOL all reduces (p＜0.01) very significantly
The prompting medicine has certain regulating action to Proteometabolism and lipid metabolism.
Table 11 administration is after one month, and the blood biochemical of animal changes (mean ± SD).
Annotate: compare with model group:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
Table 12 administration is after one month, and the blood biochemical of animal changes (mean ± SD).
Annotate: compare with model group:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
8, convalescent period animal the blood pressure testing result
After the administration one month, through one week of drug withdrawal, positive drug is compared with model group with the systolic pressure of ZF-7 group, still has significance to reduce (p＜0.05), and reduction value＞20mmHg.
After two weeks of drug withdrawal, systolic pressure, diastolic pressure and the mean arterial pressure of positive drug, ZF-7 and ZY-1 group are compared with model group, still have significance to reduce (p＜0.05), but reduction value＜20mmHg do not have biological significance.
After three weeks of drug withdrawal, each administration group is compared with model group, and significant difference is not all arranged.
Table 13 administration is after one month, through one week of over recovery, the body weight blood pressure of animal (mean ± SD).
Annotate: compare with model group:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
Table 14 administration is after one month, through two weeks of over recovery, the body weight blood pressure of animal (mean ± SD).
Annotate: compare with model group:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
Table 15 administration is after one month, through three weeks of over recovery, the body weight blood pressure of animal (mean ± SD).
Annotate: compare with model group:
*: p＜0.05;
*: p＜0.01;
* *: p＜0.001
Compositions among cited all embodiment of the present invention has the essentially identical effect with embodiment 1-4.
Compositions of the present invention has function and cures mainly: dampness eliminating to alleviate water retention, suppressing the hyperactive liver and subsiding YANG.Be used to treat the diseases such as essential hypertension that metabolism syndrome causes.Composition stable property of the present invention is good, few side effects, long shelf-life, characteristics such as therapeutic effect is remarkable.Simultaneously, method for preparing of the present invention is simple, is fit to production, and extraction ratio is high; Composition prescription is a conventional Chinese medicine in this invention, avoids the use of rare Chinese medicine and animal drugs, has reduced production cost, benefits extensive patients, is fit to promote.
Description of drawings
The variation of mean arterial pressure behind Fig. 1 single-dose
The variation that the after-contraction of Fig. 2 single-dose is pressed
The variation of a monthly average arterial pressure of Fig. 3 administration.
The variation that Fig. 4 administration after-contraction in month is pressed.
The variation of Fig. 5 administration diastolic pressure after month
Month the weight of animals of Fig. 6 administration changes
The specific embodiment:
Through following specific embodiment only is to explain content of the present invention, is not the further qualification to protection domain of the present invention.
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), be heated to boiling after, slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boiled, slow fire boiling 5min poured out medicinal liquid, and 60～65 ℃ are evaporated to dried.
Embodiment 2, pharmaceutical composition of the present invention (CT-5)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima
Full side adds 8 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 7 times of decoctings and boil 1h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution; After being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 70% to supernatant; Leave standstill 12h, filter, deposition discards, and filtrates 60～65 ℃ to be evaporated to dried.
The active substance that above technology obtains mixes with the medicine acceptable carrier, processes according to the galenic pharmacy routine techniques.
Embodiment 3 pharmaceutical compositions of the present invention (ZY-1)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima
Radix et Rhizoma Rhei (stir-fried with wine) adds 8 times 50% ethanol extraction 1h, filters, and medicinal residues add 8 times 50% ethanol extraction 1h, filters; Medicinal residues discard, merge extractive liquid,, 60～65 ℃ of 4 times of volumes that are evaporated to medical material, 15 times of volumes of thin up to medical material; Leave standstill 12h, centrifuging and taking supernatant, D101 purification (medical material amount 1.5 times), last appearance; Washing (5 column volumes), 80% ethanol elution (7 column volumes), eluent is evaporated to dried for 60～65 ℃.
Prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice adds 8 times 70% ethanol extraction 1h, filters, and medicinal residues add 8 times 70% ethanol extraction 1h, filters; Medicinal residues discard, merge extractive liquid,, 60～65 ℃ of 3 times of volumes that are evaporated to medical material; After being cooled to room temperature, adding concentrated hydrochloric acid and regulate pH to 1.5,12h is left standstill in cold preservation; Filter, filtrating discards, and gets the deposition part and is drying to obtain.
All the other flavour of a drug except that Radix et Rhizoma Rhei (stir-fried with wine) and prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 8 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter; Medicinal residues add 7 times of decoctings and boil 1h, filter, and medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10; Concentrated solution, be cooled to room temperature after, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 70% to supernatant; Leave standstill 12h, filter, deposition discards, and filtrates 60～65 ℃ to be evaporated to dried.
In the prescription ratio, with above-mentioned three kinds of dry powder blend.
Embodiment 4 pharmaceutical compositions of the present invention (ZF-7)
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima
Radix et Rhizoma Rhei (stir-fried with wine) and Semen Cassiae add 8 times 50% ethanol extraction 1h, filter, and medicinal residues add 8 times 50% ethanol extraction 1h, filter; Medicinal residues discard, merge extractive liquid,, 60～65 ℃ of 4 times of volumes that are evaporated to medical material, 15 times of volumes of thin up to medical material; Leave standstill 12h, centrifuging and taking supernatant, D101 purification (medical material amount 1.7 times), last appearance; Washing (5 column volumes), 80% ethanol elution (16 column volumes), eluent is evaporated to dried for 60～65 ℃.
Prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice adds 8 times 70% ethanol extraction 1h, filters, and medicinal residues add 8 times 70% ethanol extraction 1h, filters; Medicinal residues discard, merge extractive liquid,, 60～65 ℃ of 3 times of volumes that are evaporated to medical material; After being cooled to room temperature, adding concentrated hydrochloric acid and regulate pH to 1.5,12h is left standstill in cold preservation; Filter, filtrating discards, and gets the deposition part and is drying to obtain.
Spica Prunellae adds 13 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter; Medicinal residues add 13 times of decoctings and boil 1h, filter, and medicinal residues discard, and extracted twice liquid is merged; After being cooled to room temperature, D101 purification (medical material 1.5 times), last appearance; Washing (5 column volumes), 80% ethanol elution (medical material 15 times), eluent is evaporated to dried for 60～65 ℃.
Ramulus Uncariae Cum Uncis and Fructus Leonuri add 9 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter; Medicinal residues add 9 times of decoctings and boil 1h, filter, and medicinal residues discard, and extracted twice liquid is merged; After being cooled to room temperature, D101 purification (medical material 1.5 times), last appearance; Washing (5 column volumes), 80% ethanol elution (medical material 15 times), eluent is evaporated to dried for 60～65 ℃.
Pheretima and Monas cuspurpureus Went add 8 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 7 times of decoctings and boil 1h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 60～65 ℃ are evaporated to D60=1.05-1.10, get concentrated solution; After being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 70% to supernatant; Leave standstill 12h, filter, deposition discards, and filtrates 60～65 ℃ to be evaporated to dried.
In the prescription ratio, with above-mentioned five kinds of dry powder blend.
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 8 times of water loggings bubble 1h, be heated to boiling after, extract 2h, filter, medicinal residues add 8 times of water extraction 2h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Semen Cassiae, Fructus Leonuri add 8 times of 80% soak with ethanol 1h, be heated to boiling after, extract 2h, filter, medicinal residues add 8 times of 80% ethanol extraction 2h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Spica Prunellae, Pheretima, Monas cuspurpureus Went add 8 times of water loggings bubble 1h, be heated to boiling after, extract 2h, filter, medicinal residues add 8 times of decoctings and boil 2h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 55～65 ℃ are evaporated to density=1.05-1.20, get concentrated solution; After being cooled to room temperature, add 80-95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 60～90% to supernatant, leaves standstill 12-24h; Filter, deposition discards, and 55～65 ℃ of concentrating under reduced pressure of filtrating obtain extracting solution 3.
With extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 ℃ are evaporated to fluid extract (density=1.2～1.4) or dry powder.
Or
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 5 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 5 times of water extraction 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Semen Cassiae, Fructus Leonuri add 5 times of 60% soak with ethanol 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 5 times of 60% ethanol extraction 1h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Spica Prunellae, Pheretima, Monas cuspurpureus Went add 5 times of water loggings bubble 0.5h, be heated to boiling after, extract 1h, filter, medicinal residues add 5 times of decoctings and boil 1h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 55～65 ℃ are evaporated to density=1.05-1.20, get concentrated solution; After being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 60% to supernatant, leaves standstill 12h; Filter, deposition discards, and 55～65 ℃ of concentrating under reduced pressure of filtrating obtain extracting solution 3.
With extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 ℃ are evaporated to fluid extract (density=1.2～1.4) or dry powder.
Or
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 10 times of water loggings bubble 1h, be heated to boiling after, extract 3h, filter, medicinal residues add 10 times of water extraction 3h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1.
Ramulus Uncariae Cum Uncis, Semen Cassiae, Fructus Leonuri add 10 times of 95% soak with ethanol 1h, be heated to boiling after, extract 3h, filter, medicinal residues add 10 times of 95% ethanol extraction 3h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2.
Spica Prunellae, Pheretima, Monas cuspurpureus Went add 10 times of water loggings bubble 1h, be heated to boiling after, extract 3h, filter, medicinal residues add 10 times of decoctings and boil 3h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 55～65 ℃ are evaporated to density=1.05-1.20, get concentrated solution; After being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 90% to supernatant, leaves standstill 24h; Filter, deposition discards, and 55～65 ℃ of concentrating under reduced pressure of filtrating obtain extracting solution 3.
With extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 ℃ are evaporated to fluid extract (density=1.2～1.4) or dry powder.
Embodiment 6, granule
Get 100 parts of any pharmaceutically active substances of embodiment 1-5, add the dextrin of 1.5 times of amounts, 0.5% sucrose, 1.5% microcrystalline Cellulose is processed soft material with an amount of dissolve with ethanol, granulates, and 60 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Get 100 parts of any pharmaceutically active substances of embodiment 1-5, add 1000 parts Polyethylene Glycol, mix homogeneously, fusion, last drop pill machine is processed drop pill.
Embodiment 8, oral cavity disintegration tablet
Get 100 parts of any pharmaceutically active substances of embodiment 1-5, add 5% polyvinylpolypyrrolidone, 0.1% magnesium stearate, 50% microcrystalline Cellulose; Process soft material with an amount of alcoholic solution, granulate, 60 ℃ of forced air dryings are granulated; Granulate, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiment 9, injectable powder
Get 0.5 part of any pharmaceutically active substance of embodiment 1-5,4.5 parts of glucoses, 0.9 part in sodium thiosulfate and distilled water 1ml, behind the said components mix homogeneously, lyophilization, 500 of packing promptly get injectable powder.
Embodiment 10, capsule
Get 100 parts of any pharmaceutically active substances of embodiment 1-5, add equivalent starch, sucrose and magnesium stearate are granulated, and incapsulate, and promptly get capsule.
Embodiment 11, tablet
Get 100 parts of any pharmaceutically active substances of embodiment 1-5, with starch, sodium carboxymethyl cellulose, Pulvis Talci mix homogeneously are granulated, and tabletting promptly gets tablet.
Embodiment 12, oral liquid
Get 2 parts of any pharmaceutically active substances of embodiment 1-5, with 4 parts in syrup, be dissolved in the pure water of 100ml, homogenizing filters, through high-temperature short-time sterilization (135 ℃, 4s).Sterile filling, packing make oral liquid.
Embodiment 13, pharmaceutical composition of the present invention
15 parts of 7.5 parts of Semen Cassiaes of 3 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
22.5 parts of 15 parts of Spica Prunellaes of 15 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
3 parts in 15 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), be heated to boiling after, slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boiled, slow fire boiling 5min poured out medicinal liquid, 60～65 ℃ of concentrating under reduced pressure as for.
Embodiment 14, pharmaceutical composition of the present invention
60 parts of 30 parts of Semen Cassiaes of 12 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
90 parts of 60 parts of Spica Prunellaes of 60 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
12 parts in 60 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), be heated to boiling after, slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boiled, slow fire boiling 5min poured out medicinal liquid, and 60～65 ℃ are evaporated to dried.
Embodiment 15, pharmaceutical composition of the present invention
20 parts of 10 parts of Semen Cassiaes of 5 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
40 parts of 20 parts of Spica Prunellaes of 20 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
5 parts in 20 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), be heated to boiling after, slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boiled, slow fire boiling 5min poured out medicinal liquid, and 60～65 ℃ are evaporated to dried.
Embodiment 16, pharmaceutical composition of the present invention
40 parts of 20 parts of Semen Cassiaes of 7 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix et Rhizoma Rhei (stir-fried with wine)
50 parts of 40 parts of Spica Prunellaes of 40 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
7 parts in 40 parts of Monas cuspurpureus Went of Pheretima
The independent cold water soak of Ramulus Uncariae Cum Uncis (150mL/ prescription), all the other flavour of a drug add cold water soak 20min (700mL/ prescription), be heated to boiling after, slow fire boiling 20min.Medical material and decoction liquor and Ramulus Uncariae Cum Uncis and soak thereof merge, and after intense fire boiled, slow fire boiling 5min poured out medicinal liquid, and 60～65 ℃ are evaporated to dried.
The active substance that above different process obtains mixes with the medicine acceptable carrier, processes pharmaceutical preparations composition according to the galenic pharmacy routine techniques; Group component in the foregoing description can enlarge or reduce in scale according to the production needs simultaneously.
Claims (7)
1. a preparation of drug combination method of treating essential hypertension is characterized in that, said compositions is processed into by following bulk drugs process:
Radix Et Rhizoma Rhei 3-12 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 7.5-30 part Semen Cassiae 15-60 part
Ramulus Uncariae Cum Uncis 15-60 part Fructus Leonuri 15-60 part Spica Prunellae 22.5-90 part
Pheretima 15-60 part Monas cuspurpureus Went 3-12 part,
Said method for preparing may further comprise the steps:
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 5～10 times of water loggings bubble, 0.5～1h, be heated to boiling after, extract 1～3h, filter, medicinal residues add 5～10 times of water extraction 1～3h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1;
Ramulus Uncariae Cum Uncis, Semen Cassiae, Fructus Leonuri add 5～10 times of 60～95% soak with ethanol 0.5～1h, be heated to boiling after, extract 1～3h; Filter, medicinal residues add 5～10 times of 60～95% ethanol extraction 1～3h, filter; Medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2;
Spica Prunellae, Pheretima, Monas cuspurpureus Went add 5～10 times of water loggings bubble, 0.5～1h, be heated to boiling after, extract 1～3h, filter, medicinal residues add 5～10 times of decoctings and boil 1～3h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 55～65 ℃ are evaporated to density=1.05-1.20, get concentrated solution; After being cooled to room temperature, add 95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 60～90% to supernatant, leaves standstill 12h; Filter, deposition discards, and 55～65 ℃ of concentrating under reduced pressure of filtrating obtain extracting solution 3;
With extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 ℃ are evaporated to fluid extract (density=1.2～1.4) or dry powder;
The active substance that above technology obtains mixes with the medicine acceptable carrier, processes according to the galenic pharmacy routine techniques.
2. method for preparing according to claim 1 is characterized in that, said compositions is processed into by following bulk drugs process:
Radix Et Rhizoma Rhei 5-7 part prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice 10-20 part Semen Cassiae 20-40 part
Ramulus Uncariae Cum Uncis 20-40 part Fructus Leonuri 20-40 part Spica Prunellae 40-50 part
Pheretima 20-40 part Monas cuspurpureus Went 5-7 part.
3. method for preparing according to claim 2 is characterized in that, said compositions is processed into by following bulk drugs process:
30 parts of 15 parts of Semen Cassiaes of 6 parts of prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice of Radix Et Rhizoma Rhei
45 parts of 30 parts of Spica Prunellaes of 30 parts of Fructus Leonuris of Ramulus Uncariae Cum Uncis
6 parts in 30 parts of Monas cuspurpureus Went of Pheretima.
4. according to said any one method for preparing of claim 1-3, wherein said compositions contains the medicine acceptable carrier.
5. according to said any one method for preparing of claim 4, wherein said compositions is any pharmaceutically useful dosage form.
6. according to said any one method for preparing of claim 5, wherein said compositions is a peroral dosage form.
7. the described method for preparing of claim 1 is characterized in that, may further comprise the steps:
Radix et Rhizoma Rhei (stir-fried with wine), prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice add 8 times of water loggings bubble 1h, be heated to boiling after, extract 2h, filter, medicinal residues add 8 times of water extraction 2h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 1;
Ramulus Uncariae Cum Uncis, Semen Cassiae, Fructus Leonuri add 8 times of 80% soak with ethanol 1h, be heated to boiling after, extract 2h, filter, medicinal residues add 8 times of 80% ethanol extraction 2h, filter, medicinal residues discard, and extracted twice liquid is merged, and obtain extracting solution 2;
Spica Prunellae, Pheretima, Monas cuspurpureus Went add 8 times of water loggings bubble 1h, be heated to boiling after, extract 2h, filter, medicinal residues add 8 times of decoctings and boil 2h; Filter, medicinal residues discard, and extracted twice liquid is merged, and 55～65 ℃ are evaporated to density=1.05-1.20, get concentrated solution; After being cooled to room temperature, add 80-95% ethanol precipitate with ethanol, the limit edged stirs, and contains alcohol 60～90% to supernatant, leaves standstill 12-24h; Filter, deposition discards, and 55～65 ℃ of concentrating under reduced pressure of filtrating obtain extracting solution 3;
With extracting solution 1, extracting solution 2 and extracting solution 3 mix homogeneously, 55～65 ℃ are evaporated to fluid extract (density=1.2～1.4) or dry powder;
The pharmaceutically active substance that more than obtains, this active substance mixes with the medicine acceptable carrier, processes according to the galenic pharmacy routine techniques.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010564324.XA CN102475780B (en) | 2010-11-29 | 2010-11-29 | Preparation method for traditional Chinese drug composition for treating primary hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010564324.XA CN102475780B (en) | 2010-11-29 | 2010-11-29 | Preparation method for traditional Chinese drug composition for treating primary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102475780A true CN102475780A (en) | 2012-05-30 |
| CN102475780B CN102475780B (en) | 2014-12-03 |
Family
ID=46088638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010564324.XA Expired - Fee Related CN102475780B (en) | 2010-11-29 | 2010-11-29 | Preparation method for traditional Chinese drug composition for treating primary hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102475780B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050025843A1 (en) * | 2001-12-21 | 2005-02-03 | Chung Shen | Herbal pharmaceutical compositions for prophylaxis and/or treatment of cardiovascular diseases and the method of preparing the same |
| CN1657085A (en) * | 2004-09-06 | 2005-08-24 | 青岛国风药业股份有限公司 | Oral Chinese medicinal composition for treating hypertension |
| CN101579480A (en) * | 2008-05-15 | 2009-11-18 | 北京北大维信生物科技有限公司 | Medicinal dripping pill for treating hypertension |
-
2010
- 2010-11-29 CN CN201010564324.XA patent/CN102475780B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050025843A1 (en) * | 2001-12-21 | 2005-02-03 | Chung Shen | Herbal pharmaceutical compositions for prophylaxis and/or treatment of cardiovascular diseases and the method of preparing the same |
| CN1657085A (en) * | 2004-09-06 | 2005-08-24 | 青岛国风药业股份有限公司 | Oral Chinese medicinal composition for treating hypertension |
| CN101579480A (en) * | 2008-05-15 | 2009-11-18 | 北京北大维信生物科技有限公司 | Medicinal dripping pill for treating hypertension |
Non-Patent Citations (1)
| Title |
|---|
| 张莉: "大黄、红曲配伍方案干预颈动脉粥样硬化斑块的临床研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 11, 15 November 2009 (2009-11-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102475780B (en) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| CN105878322A (en) | Sunflower head extract prepared by crystallization enzymolysis method and preparation method of sunflower head extract | |
| CN113082166A (en) | Method for preparing health food from herba Dendrobii | |
| CN104666373A (en) | Novel use of Eurycoma longifolia Jack | |
| CN106535912B (en) | Control pharmaceutical composition and its application of human body blood fat and body weight | |
| CN102716283B (en) | Hypolipidemic traditional Chinese medicine | |
| CN100509009C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN102670785B (en) | Preparation method of conventional Chinese medicine composition for treating primary hypertension | |
| CN103191221A (en) | Antiobesity effect of hedan preparation | |
| CN102475780B (en) | Preparation method for traditional Chinese drug composition for treating primary hypertension | |
| CN102475778B (en) | Preparation method for traditional Chinese medicinal composition used for treating essential hypertension | |
| CN102475781B (en) | Method for preparing traditional Chinese medicine composition used for treating essential hypertension | |
| CN102475782B (en) | Preparation method of traditional Chinese medicinal composition for treating primary hypertension | |
| CN102475779B (en) | Preparation method of traditional Chinese medicine composition for treating primary hypertension | |
| CN102475784B (en) | Chinese medicinal composition for treating essential hypertension and its preparation method | |
| CN102475785B (en) | Preparation method of Chinese medicinal composition for treating essential hypertension | |
| CN102475783B (en) | Preparation method of traditional Chinese medicinal composition for treating primary hypertension | |
| CN101744991B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN101574454B (en) | Restoration traditional Chinese medicine | |
| CN107753551B (en) | Composition with function of reducing blood pressure and preparation method thereof | |
| CN102552399B (en) | Traditional Chinese medicinal composition for clearing heat and calming liver and preparation method thereof | |
| CN103830563B (en) | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141203 Termination date: 20181129 |